DDD stages

Phase 3 trials

Novartis remibrutinib significantly reduces relapse rates and shows favourable safety profile in phase 3 RMS trials

Novartis has announced positive topline results from its phase 3 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib, a highly selective and potent oral Bruton’s...
Read more
Phase 1-2 trials

GSK to advance mRNA seasonal flu vaccine candidate to phase 3 following positive phase 2 data

GSK presented positive phase 2 data for its mRNA seasonal influenza (flu) vaccine candidate at the Options XIII Conference for the Control of Influenza. GSK’s...
Read more
Phase 3 trials

New phase 3b data on Eli Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults...

Eli Lilly and Company (NYSE: LLY) has announced 52-week results from Together-PsO and Together-PsA, two novel open-label phase 3b clinical trials evaluating the concomitant use of...
Read more
Phase 3 trials

Acoramidis demonstrates reversal of cardiac structural disease progression and functional decline and significantly increases days alive and free from hospitalisation in ATTR-CM

BridgeBio Pharma has presented new analyses from the phase 3 study of Attruby (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR-CM), including the cardiac magnetic resonance...
Read more
Phase 3 trials

Tezspire demonstrates positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints

Amgen and AstraZeneca have announced positive top-line results from the phase 3 trial of Tezspire (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE). Tezspire demonstrated statistically...
Read more
Phase 3 trials

Late-breaking data for Abbott’s Tactiflex Duo Ablation Catheter reveal positive outcomes for treating complex AFib cases

Abbott, the global healthcare leader, has announced new late-breaking 12-month data from the FlexPulse Global IDE study that show favourable safety and effectiveness outcomes...
Read more
Phase 1-2 trials

Teva announces positive topline results from phase 2a study in celiac disease for its anti-IL-15 antibody, further validating its pipeline-in-a-product potential

Teva Pharmaceutical has announced positive topline results from an ongoing phase 2a study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with...
Read more
Phase 3 trials

Raziel Therapeutics and Fosun Pharma announce positive phase 3 results for RZL-012 in submental fat reduction, clearing the path to a China NDA filing

Raziel Therapeutics has announced positive results from its phase 3 registration trial in China evaluating RZL-012 for the reduction of submental fat (SMF –...
Read more
- Advertisement -
ILMAC ad
- Advertisement -
BIO Europe
- Advertisement -WVC EU

Latest posts

Load more

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions. Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

Menu

© Web design by Social Media Services 2026. All rights reserved.

Click to listen highlighted text!